Every 8-K that ARCELLX INC (ACLX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ACLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACLX filings page.
Arcellx, Inc. has been acquired by Gilead Sciences through a completed tender offer and merger. Stockholders receive $115.00 in cash per share plus one contingent value right (CVR) that may pay $5.00 in cash if specified anito-cel sales milestones are achieved by December 31, 2029.
The offer closed with 38,795,604 shares tendered, representing about 77.2% of outstanding shares, and Gilead used approximately $7.1 billion to fund the transaction. Arcellx is now a wholly owned Gilead subsidiary, its directors and officers have been replaced by Gilead designees, its charter and bylaws were restated, and its Nasdaq listing and SEC registration are being terminated.
Arcellx, Inc. agreed to be acquired by Gilead Sciences through a tender offer followed by a merger. Holders of Arcellx common stock will be offered $115.00 in cash plus one contingent value right (CVR) per share, with each CVR paying $5.00 in cash if cumulative worldwide sales of anito-cel reach $6.0 billion by December 31, 2029.
The tender offer must secure more than 50% of outstanding shares and satisfy antitrust and other customary conditions; it is not subject to a financing condition. Support agreements cover approximately 10.3% of Arcellx shares, and Gilead already owns about 11.5%. A $260 million termination fee may be payable in certain circumstances.
The U.S. FDA has accepted the Biologic License Application for anito-cel, a BCMA-targeting CAR T-cell therapy for relapsed or refractory multiple myeloma, with a Prescription Drug User Fee Act (PDUFA) action date of December 23, 2026.
Arcellx, Inc. furnished a current report on Form 8-K to announce that it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated. The report lists ACLX as the trading symbol on The Nasdaq Stock Market LLC and is signed by Chief Executive Officer Rami Elghandour on November 5, 2025.